Now It's Time To Buy These 3 IPOs

Monday, June 21, 2021 | Thomas Hughes
Now Its Time To Buy These 3 IPOs

The Analysts Are Buzzing About These 3 Stocks 

The quiet period on three of the hottest IPOs of the spring has just come to an end and the analysts are already speaking up. Based on the chatter, these stocks should do well over the summer and this year. Based on the business models, fundamentals, and the outlook for earnings these stocks should do very well over the long term.

Day One Biopharmaceuticals Is Bottoming

Day One Biopharmaceuticals (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on childhood cancers. The stock popped in the wake of the IPO but has since pulled back to what we believe it's becoming a very firm support level. The company's lead drug candidate is called Day101, it was designed to be a highly selective fibrosarcoma kinase inhibitor to fight brain and spine cancers. The company is planning to launch a phase II trial fairly soon targeting the most common form of brain tumors found in young people.

So far, 4 sell-siders have come out with positive commentary on Day One Biopharmaceuticals. All four rated the company a Strong Buy with a price target of $21. Looking at the chart, the stock appears to be bottoming and is on track to soon exceed the $21 level. If we get a move above $21, we expect to see the analysts begin upping their price targets and for the stock to move towards the $26 level.

Now Its Time To Buy These Three IPOs

Fintech Flywire Poised To Set New Highs

Shares of Flywire (NASDAQ: FLYW) had a strong day on the IPO but have pulled back in the time since. Now, with the stock already rebounding on positive news, the analysts are accelerating the move. Price action appears to have put in a V-bottom and is on track to retest the post-IPO high very soon. A move above $35 would be very bullish and could leave this doc up to the 45 to $55 range.

As for the good news?  Flywire is expanding the comprehensive solutions that it offers to Canadian institutions. The company is an electronic payment processor focused on educational, healthcare travel, and business-to-business payments, a fintech segment that Flywire estimated to be worth $11.7 trillion annually. So far there have been 10 sell-siders to come out with positive comments on the stock. The consensus rating is a Buy verging on Strong Buy with a consensus price target in the range of $39 to $45.

Now Its Time To Buy These Three IPOs

Figs Grows To New Highs On Analyst Sentiment

Figs (NYSE: FIGS) is an interesting company in that it manufactures and markets apparel to the healthcare industry via e-commerce. In today's market, we like apparel, anything work-related, health care, and e-commerce so there's a lot to like about this company.  The stock has received 10 analysts nods in the wake of the quiet period with a consensus that amounts to a Strong Buy. The range of analysts’ price targets runs from $28 to $50 but the concentration is in the $40 to $50 range. The stock has performed strongly post-IPO and it looks ready to set a new all-time high today. A move above $38 would be very bullish and could take the stock up to the $40 to $42 range.

Now Its Time To Buy These Three IPOs

Should you invest $1,000 in right now?

Before you consider , you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and wasn't on the list.

While currently has a "" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 


Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Flywire (FLYW)2.0$32.05+0.9%N/AN/ABuy$41.50
Day One Biopharmaceuticals (DAWN)1.7$23.91+0.8%N/AN/ABuy$37.33
Compare These Stocks  Add These Stocks to My Watchlist 

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.